EUVIMEDEUVIMED entdecken
Crossref

CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies

Guillermo Ureña-Bailén, Andrés Lamsfus-Calle, Alberto Daniel-Moreno, Janani Raju, Patrick Schlegel, Christian Seitz, Daniel Atar, Justin S Antony, Rupert Handgretinger, Markus Mezger

Briefings in Functional Genomics · 20.05.2020 · 19 (3) · 191-200

DOI: 10.1093/bfgp/elz039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Briefings in Functional Genomics, online erschienen am 13.12.2019. Verfasst von Guillermo Ureña-Bailén und 9 weiteren Autor:innen. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 91 Literaturangaben. Gefördert von: Förderverein für krebskranke Kinder Tübingen, Jürgen Manchot Stiftung, Clinician Scientist Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR)-modified T cells have raised among other immunotherapies for cancer treatment, being implemented against B-cell malignancies. Despite the promising outcomes of this innovative technology, CAR-T cells are not exempt from limitations that must yet to be overcome in order to provide reliable and more efficient treatments against other types of cancer. The purpose of this review is to shed light on the field of CAR-T cell gene editing for therapy universalization and further enhancement of antitumor function. Several studies have proven that the disruption of certain key genes is essential to boost immunosuppressive resistance, prevention of fratricide, and clinical safety. Due to its unparalleled simplicity, feasibility to edit multiple gene targets simultaneously, and affordability, CRISPR/CRISPR-associated protein 9 system has been proposed in different clinical trials for such CAR-T cell improvement. The combination of such powerful technologies is expected to provide a new generation of CAR-T cell-based immunotherapies for clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsGene EditingHumansImmunotherapy

Stichwörter der Autor:innen

CAR-T cellCRISPR/Cas9cancerclinical applicationgene editingimmunotherapy

Förderung

  • Förderverein für krebskranke Kinder Tübingen
  • Jürgen Manchot Stiftung
  • Clinician Scientist Program
  • University Children’s Hospital

Zitieren

APA

Ureña-Bailén, G., Lamsfus-Calle, A., Daniel-Moreno, A., Raju, J., Schlegel, P., Seitz, C., Atar, D., Antony, J. S., Handgretinger, R., & Mezger, M. (2020). CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies. Briefings in Functional Genomics, 19(3), 191-200. https://doi.org/10.1093/bfgp/elz039

Vancouver

Ureña-Bailén G, Lamsfus-Calle A, Daniel-Moreno A, Raju J, Schlegel P, Seitz C, et al. CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies. Briefings in Functional Genomics. 2020;19(3):191-200. doi:10.1093/bfgp/elz039

BibTeX
@article{UreaBailn2020,
  author = {Ureña-Bailén, Guillermo and Lamsfus-Calle, Andrés and Daniel-Moreno, Alberto and Raju, Janani and Schlegel, Patrick and Seitz, Christian and Atar, Daniel and Antony, Justin S and Handgretinger, Rupert and Mezger, Markus},
  title = {CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies},
  journal = {Briefings in Functional Genomics},
  year = {2020},
  volume = {19},
  number = {3},
  pages = {191--200},
  doi = {10.1093/bfgp/elz039}
}
Kostenlos starten →